The global inhalation and nasal spray generic drugs market size is expected to reach US$37.4 bn in revenue by 2026. It is therefore expected to display a CAGR of 6.8% from 2019 to 2026.
This report on the inhalation and nasal spray generic drugs market studies the current and future prospects of the global market. Growing incidences of respiratory diseases such as asthma and COPD, increasing geriatric population, and increasing number of generic manufacturers is expected to accentuate the growth of inhalation and nasal spray generic drugs market globally. The inhalation and nasal spray generic drugs market report comprises an elaborate executive summary, which includes a market snapshot that provides information about various segments and sub-segments of the market. It also provides information and data analysis of the global inhalation and nasal spray generic drugs market with respect to market segments based on drug class, medical indication and their geographic analysis.
Based on drug class, the inhalation and nasal spray generic drugs market has been segmented into five major categories: corticosteroids, bronchodilators, antihistamines, combinations, and decongestant sprays. The market segments have been extensively analyzed based on usefulness, efficacy, revenue, and geographical coverage. The market size and forecast in terms of US$ Mn for each segment has been provided for the period from 2016 to 2026. The report also provides the compound annual growth rate (CAGR %) for each market segment for the forecast period from 2019 to 2026, considering 2018 as the base year.
Geographically, the global inhalation and nasal spray generic drugs market has been categorized into six major regions: North America, Europe, Asia Pacific, Latin America, Middle East and North Africa, and Rest of the World. The market size and forecast for each of these regions has been provided for the period from 2016 to 2026, along with their respective CAGRs for the forecast period from 2019 to 2026, considering 2018 as the base year. The research study also covers the competitive scenario in these regions. A detailed qualitative analysis of factors responsible for driving and restraining the growth of the market and future opportunities has been provided in the market overview section. This section of the report also provides market attractiveness analysis by drug class and geography, as well as market share analysis by key players, thus presenting a thorough analysis of the overall competitive scenario in the global inhalation and nasal spray generic drugs market.
Current and future trends has also been provided for new entrants as well as existing market players to assist them in taking strategic initiatives to establish a strong presence in the market. The report also profiles major players in the inhalation and nasal spray generic drugs market based on various attributes such as company overview, financial overview, product portfolio, business strategies, and recent developments. Major players profiled in this report include Teva Pharmaceutical Industries Ltd., Sandoz International GmbH (Novartis AG), Allergan plc, Mylan N.V., Ranbaxy Laboraotries Ltd., Roxane Laboratories, Inc., Beximco Pharmaceuticals Ltd., Cipla Ltd., and Nephron Pharmaceuticals Corporation.
The global inhalation and nasal spray generic drugs market is segmented as given below:
Global Inhalation and Nasal Spray Generic Drugs Market, by Drug Class, 2016-2026 (US$ Mn)
Global Inhalation and Nasal Spray Generic Drugs Market, by Drug Class, 2016-2026 (US$ Mn)
Global Inhalation and Nasal Spray Generic Drugs Market, by Geography, 2016 – 2026 (US$ Mn)
1. Preface
1.1. Report Description
1.2. Market Segmentation
1.3. Research Methodology
2. Executive Summary
2.1. Global Inhalation and Nasal Spray Generic Drugs Market Revenue, 2016–2026 (US$ Mn)
2.2. Global Inhalation and Nasal Spray Generic Drugs Market Revenue, by Drug Class, 2018 (US$ Mn)
2.3. Global Inhalation and Nasal Spray Generic Drugs Market Revenue, by Medical Indication, 2018 (US$ Mn)
2.4. Global Market Share by Geography, 2018 and 2026 (Value %)
2.5. Inhalation and Nasal Spray Generic Drugs Market Snapshot
3. Global Inhalation and Nasal Spray Generic Drugs Market – Industry Analysis
3.1. Introduction
3.2. Drivers
3.2.1. Rise in incidence of asthma, COPD, and other respiratory diseases to provide an impetus for growth
3.2.2. Low cost involved with generic prescription drugs
3.3. Restraints
3.3.1. Stringent regulatory policies for generic drugs in developing countries
3.1. Opportunities
3.1.1. Patent expiry of blockbuster drugs would provide new opportunities for generic drug manufacturers
3.2. Market Attractiveness Analysis – Inhalation and Nasal Spray Generic Drugs Market, By Drug Class
3.3. Market Attractiveness Analysis – Inhalation and Nasal Spray Generic Drugs Market, By Geography
3.4. Company Market Share – Inhalation and Nasal Spray Generic Drugs Market (2018) (%)
3.5. Patient Pool Analysis, by Medical Indication
3.6. Regulatory Framework for U.S.
3.7. Regulatory Framework for Europe
4. Market Segmentation – By Drug Class
4.1. Introduction
4.2. Global Corticosteroids Market for Inhalation and Nasal Spray Generic Drugs, 2016–2026 (US$ Mn)
4.2.1. Global Fluticasone Market for Inhalation and Nasal Spray Generic Drugs, 2016–2026 (US$ Mn)
4.2.2. Global Budesonide Market for Inhalation and Nasal Spray Generic Drugs, 2016–2026 (US$ Mn)
4.2.3. Global Beclomethasone Market for Inhalation and Nasal Spray Generic Drugs, 2016–2026 (US$ Mn)
4.2.4. Global Flunisolide Market for Inhalation and Nasal Spray Generic Drugs, 2016–2026 (US$ Mn)
4.2.5. Global Other Corticosteroids Market for Inhalation and Nasal Spray Generic Drugs, 2016–2026 (US$ Mn)
4.3. Global Bronchodilators Market for Inhalation and Nasal Spray Generic Drugs, 2016–2026 (US$ Mn)
4.3.1. Global Albuterol Market for Inhalation and Nasal Spray Generic Drugs, 2016–2026 (US$ Mn)
4.3.2. Global Epinephrine Market for Inhalation and Nasal Spray Generic Drugs, 2016–2026 (US$ Mn)
4.3.3. Global Other Bronchodilators Market for Inhalation and Nasal Spray Generic Drugs, 2016–2026 (US$ Mn)
4.4. Global Antihistamines Market for Inhalation and Nasal Spray Generic Drugs, 2016–2026 (US$ Mn)
4.5. Global Combinations Market for Inhalation and Nasal Spray Generic Drugs, 2016–2026 (US$ Mn)
4.5.1. Global Salmeterol/Fluticasone Market for Inhalation and Nasal Spray Generic Drugs, 2016–2026 (US$ Mn)
4.5.2. Global Formoterol/Budesonide Market for Inhalation and Nasal Spray Generic Drugs, 2016–2026 (US$ Mn)
4.5.3. Global Azelastine/Benzalkonium Chloride Market for Inhalation and Nasal Spray Generic Drugs, 2016–2026 (US$ Mn)
4.5.4. Global Other Combination Drugs Market for Inhalation and Nasal Spray Generic Drugs, 2016–2026 (US$ Mn)
4.6. Global Decongestant Sprays Market for Inhalation and Nasal Spray Generic Drugs, 2016–2026 (US$ Mn)
4.6.1. Global Phenylephrine Hydrochloride Market for Inhalation and Nasal Spray Generic Drugs, 2016–2026 (US$ Mn)
4.6.2. Global Oxymetazoline Hydrochloride Market for Inhalation and Nasal Spray Generic Drugs, 2016–2026 (US$ Mn)
5. Market Segmentation – By Medical Indication
5.1. Introduction
5.2. Global Inhalation and Nasal Spray Generic Drugs Market for Asthma, 2016–2026 (US$ Mn)
5.3. Global Inhalation and Nasal Spray Generic Drugs Market for COPD, 2016–2026 (US$ Mn)
5.4. Global Inhalation and Nasal Spray Generic Drugs Market for Allergic Rhinitis, 2016–2026 (US$ Mn)
5.5. Global Inhalation and Nasal Spray Generic Drugs Market for Other Respiratory Disorders, 2016–2026 (US$ Mn)
6. Inhalation and Nasal Spray Generic Drugs Market - Regional Analysis
6.1. Global Inhalation and Nasal Spray Generic Drugs Market: Regional Overview
6.2. North America Inhalation and Nasal Spray Generic Drugs Market Overview
6.3. Europe Inhalation and Nasal Spray Generic Drugs Market Overview
6.4. Asia Pacific Inhalation and Nasal Spray Generic Drugs Market Overview
6.5. Latin America Inhalation and Nasal Spray Generic Drugs Market Overview
6.6. Middle East and North Africa Inhalation and Nasal Spray Generic Drugs Market Overview
6.7. RoW Inhalation and Nasal Spray Generic Drugs Market Overview
7. Historical Snapshot and Current Trends
8. Company Profiles.
8.1. Allergan plc
8.2. Beximco Pharmaceuticals
8.3. Cipla Ltd.
8.4. Mylan N.V.
8.5. Nephron Pharmaceuticals Corporation
8.6. Ranbaxy Laboratories Ltd.
8.7. Roxane Laboratories, Inc.
8.8. Sandoz International GmbH (Novartis AG)
8.9. Teva Pharmaceutical Industries Ltd.
Cross-segment Market Size and Analysis for
Mentioned Segments
Additional Company Profiles (Upto 5 With No Cost)
Additional Countries (Apart From Mentioned Countries)
Country/Region-specific Report
Go To Market Strategy
Region Specific Market DynamicsRegion Level Market Share Import Export AnalysisProduction AnalysisOthers